22
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      The road ahead in genetics and genomics

      review-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          In celebration of the 20th anniversary of Nature Reviews Genetics, we asked 12 leading researchers to reflect on the key challenges and opportunities faced by the field of genetics and genomics. Keeping their particular research area in mind, they take stock of the current state of play and emphasize the work that remains to be done over the next few years so that, ultimately, the benefits of genetic and genomic research can be felt by everyone.

          Abstract

          To celebrate the first 20 years of Nature Reviews Genetics, we asked 12 leading scientists to reflect on the key challenges and opportunities faced by the field of genetics and genomics.

          The contributors

          Amy L. McGuire is the Leon Jaworski Professor of Biomedical Ethics and Director of the Center for Medical Ethics and Health Policy at Baylor College of Medicine. She has received numerous teaching awards at Baylor College of Medicine, was recognized by the Texas Executive Women as a Woman on the Move in 2016 and was invited to give a TedMed talk titled “There is No Genome for the Human Spirit” in 2014. In 2020, she was elected as a Hastings Center Fellow. Her research focuses on ethical and policy issues related to emerging technologies, with a particular focus on genomic research, personalized medicine and the clinical integration of novel neurotechnologies.

          Stacey Gabriel is the Senior Director of the Genomics Platform at the Broad Institute since 2012 and has led platform development, execution and operation since its founding. She is Chair of Institute Scientists and serves on the institute’s executive leadership team. She is widely recognized as a leader in genomic technology and project execution. She has led the Broad’s contributions to numerous flagship projects in human genetics, including the International HapMap Project, the 1000 Genomes Project, The Cancer Genome Atlas, the National Heart, Lung, and Blood Institute’s Exome Sequencing Project and the TOPMed programme. She is Principal Investigator of the Broad’s All of Us (AoU) Genomics Center and serves on the AoU Program Steering Committee.

          Sarah A. Tishkoff is the David and Lyn Silfen University Associate Professor in Genetics and Biology at the University of Pennsylvania, Philadelphia, USA, and holds appointments in the School of Medicine and the School of Arts and Sciences. She is a member of the US National Academy of Sciences and a recipient of an NIH Pioneer Award, a David and Lucile Packard Career Award, a Burroughs/Wellcome Fund Career Award and an American Society of Human Genetics Curt Stern Award. Her work focuses on genomic variation in Africa, human evolutionary history, the genetic basis of adaptation and phenotypic variation in Africa, and the genetic basis of susceptibility to infectious disease in Africa.

          Ambroise Wonkam is Professor of Medical Genetics, Director of GeneMAP (Genetic Medicine of African Populations Research Centre) and Deputy Dean Research in the Faculty of Health Sciences, University of Cape Town, South Africa. He has successfully led numerous NIH- and Wellcome Trust-funded projects over the past decade to investigate clinical variability in sickle cell disease, hearing impairment genetics and the return of individual findings in genetic research in Africa. He won the competitive Clinical Genetics Society International Award for 2014 from the British Society of Genetic Medicine. He is president of the African Society of Human Genetics.

          Aravinda Chakravarti is Director of the Center for Human Genetics and Genomics, the Muriel G. and George W. Singer Professor of Neuroscience and Physiology, and Professor of Medicine at New York University School of Medicine. He is an elected member of the US National Academy of Sciences, the US National Academy of Medicine and the Indian National Science Academy. He has been a key participant in the Human Genome Project, the International HapMap Project and the 1000 Genomes Project. His research attempts to understand the molecular basis of multifactorial disease. He was awarded the 2013 William Allan Award by the American Society of Human Genetics and the 2018 Chen Award by the Human Genome Organization.

          Eileen E. M. Furlong is Head of the Genome Biology Department at the European Molecular Biology Laboratory (EMBL) and a member of the EMBL Directorate. She is an elected member of the European Molecular Biology Organization (EMBO) and the Academia Europaea, and a European Research Council (ERC) advanced investigator. Her group dissects fundamental principles of how the genome is regulated and how it drives cell fate decisions during embryonic development, including how developmental enhancers are organized and function within the 3D nucleus. Her work combines genetics, (single-cell) genomics, imaging and computational approaches to understand these processes. Her research has advanced the development of genomic methods for use in complex multicellular organisms.

          Barbara Treutlein is Associate Professor of Quantitative Developmental Biology in the Department of Biosystems Science and Engineering of ETH Zurich in Basel, Switzerland. Her group uses and develops single-cell genomics approaches in combination with stem cell-based 2D and 3D culture systems to study how human organs develop and regenerate and how cell fate is regulated. For her work, Barbara has received multiple awards, including the Friedmund Neumann Prize of the Schering Foundation, the Dr. Susan Lim Award for Outstanding Young Investigator of the International Society of Stem Cell Research and the EMBO Young Investigator Award.

          Alexander Meissner is a scientific member of the Max Planck Society and currently Managing Director of the Max Planck Institute (MPI) for Molecular Genetics in Berlin, Germany. He heads the Department of Genome Regulation and is a visiting scientist in the Department of Stem Cell and Regenerative Biology at Harvard University. Before his move to the MPI, he was a tenured professor at Harvard University and a senior associate member of the Broad Institute, where he co-directed the epigenomics programme. In 2018, he was elected as an EMBO member. His laboratory uses genomic tools to study developmental and disease biology with a particular focus on epigenetic regulation.

          Howard Y. Chang is the Virginia and D. K. Ludwig Professor of Cancer Genomics at Stanford University and an investigator at the Howard Hughes Medical Institute. He is a physician–scientist who has focused on deciphering the hidden information in the non-coding genome. His laboratory is best known for studies of long non-coding RNAs in gene regulation and development of new epigenomic technologies. He is an elected member of the US National Academy of Sciences, the US National Academy of Medicine, and the American Academy of Arts and Sciences.

          Núria López-Bigas is ICREA research Professor at the Institute for Research in Biomedicine and Associate Professor at the University Pompeu Fabra. She obtained an ERC Consolidator Grant in 2015 and was elected as an EMBO member in 2016. Her work has been recognized with the prestigious Banc de Sabadell Award for Research in Biomedicine, the Catalan National Award for Young Research Talent and the Career Development Award from the Human Frontier Science Program. Her research focuses on the identification of cancer driver mutations, genes and pathways across tumour types and in understanding the mutational processes that lead to the accumulation of mutations in cancer cells.

          Eran Segal is Professor in the Department of Computer Science and Applied Mathematics at the Weizmann Institute of Science, heading a multidisciplinary laboratory with extensive experience in machine learning, computational biology and analysis of heterogeneous high-throughput genomic data. His research focuses on the microbiome, nutrition and genetics, and their effect on health and disease and aims to develop personalized medicine based on big data from human cohorts. He has published more than 150 publications and received several awards and honours for his work, including the Overton and the Michael Bruno awards. He was recently elected as an EMBO member and as a member of the Israel Young Academy.

          Jin-Soo Kim is Director of the Center for Genome Engineering in the Institute for Basic Science in Daejon, South Korea. He has received numerous awards, including the 2017 Asan Award in Medicine, the 2017 Yumin Award in Science and the 2019 Research Excellence Award (Federation of Asian and Oceanian Biochemists and Molecular Biologists). He was featured as one of ten Science Stars of East Asia in Nature ( 558, 502–510 (2018)) and has been recognized as a highly cited researcher by Clarivate Analytics since 2018. His work focuses on developing tools for genome editing in biomedical research.

          Related collections

          Most cited references62

          • Record: found
          • Abstract: not found
          • Article: not found

          Genome editing with CRISPR–Cas nucleases, base editors, transposases and prime editors

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Repair of double-strand breaks induced by CRISPR–Cas9 leads to large deletions and complex rearrangements

            CRISPR-Cas9 is poised to become the gene editing tool of choice in clinical contexts. Thus far, exploration of Cas9-induced genetic alterations has been limited to the immediate vicinity of the target site and distal off-target sequences, leading to the conclusion that CRISPR-Cas9 was reasonably specific. Here we report significant on-target mutagenesis, such as large deletions and more complex genomic rearrangements at the targeted sites in mouse embryonic stem cells, mouse hematopoietic progenitors and a human differentiated cell line. Using long-read sequencing and long-range PCR genotyping, we show that DNA breaks introduced by single-guide RNA/Cas9 frequently resolved into deletions extending over many kilobases. Furthermore, lesions distal to the cut site and crossover events were identified. The observed genomic damage in mitotically active cells caused by CRISPR-Cas9 editing may have pathogenic consequences.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              A compendium of mutational cancer driver genes

              A fundamental goal in cancer research is to understand the mechanisms of cell transformation. This is key to developing more efficient cancer detection methods and therapeutic approaches. One milestone towards this objective is the identification of all the genes with mutations capable of driving tumours. Since the 1970s, the list of cancer genes has been growing steadily. Because cancer driver genes are under positive selection in tumorigenesis, their observed patterns of somatic mutations across tumours in a cohort deviate from those expected from neutral mutagenesis. These deviations, which constitute signals of positive selection, may be detected by carefully designed bioinformatics methods, which have become the state of the art in the identification of driver genes. A systematic approach combining several of these signals could lead to a compendium of mutational cancer genes. In this Review, we present the Integrative OncoGenomics (IntOGen) pipeline, an implementation of such an approach to obtain the compendium of mutational cancer drivers. Its application to somatic mutations of more than 28,000 tumours of 66 cancer types reveals 568 cancer genes and points towards their mechanisms of tumorigenesis. The application of this approach to the ever-growing datasets of somatic tumour mutations will support the continuous refinement of our knowledge of the genetic basis of cancer.
                Bookmark

                Author and article information

                Contributors
                amcguire@bcm.edu
                stacey@broadinstitute.org
                tishkoff@pennmedicine.upenn.edu
                ambroise.wonkam@uct.ac.za
                aravinda.chakravarti@nyulangone.org
                furlong@embl.de
                barbara.treutlein@bsse.ethz.ch
                meissner@molgen.mpg.de
                howchang@stanford.edu
                nuria.lopez@irbbarcelona.org
                eran.segal@weizmann.ac.il
                jskim01@snu.ac.kr
                Journal
                Nat Rev Genet
                Nat. Rev. Genet
                Nature Reviews. Genetics
                Nature Publishing Group UK (London )
                1471-0056
                1471-0064
                24 August 2020
                : 1-16
                Affiliations
                [1 ]ISNI 0000 0001 2160 926X, GRID grid.39382.33, Center for Medical Ethics and Health Policy, Baylor College of Medicine, ; Houston, TX USA
                [2 ]GRID grid.66859.34, Broad Institute of MIT and Harvard, ; Cambridge, MA USA
                [3 ]ISNI 0000 0004 1936 8972, GRID grid.25879.31, Department of Genetics, , University of Pennsylvania, ; Philadelphia, PA USA
                [4 ]ISNI 0000 0004 1936 8972, GRID grid.25879.31, Department of Biology, , University of Pennsylvania, ; Philadelphia, PA USA
                [5 ]ISNI 0000 0004 1937 1151, GRID grid.7836.a, Department of Medicine, Faculty of Health Sciences, , University of Cape Town, ; Cape Town, South Africa
                [6 ]ISNI 0000 0004 1937 1151, GRID grid.7836.a, Institute of Infectious Diseases and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, ; Cape Town, South Africa
                [7 ]ISNI 0000 0004 1936 8753, GRID grid.137628.9, Center for Human Genetics and Genomics, , New York University Grossman School of Medicine, ; New York, NY USA
                [8 ]ISNI 0000 0004 0495 846X, GRID grid.4709.a, European Molecular Biology Laboratory, Genome Biology Department, ; Heidelberg, Germany
                [9 ]ISNI 0000 0001 2156 2780, GRID grid.5801.c, Department of Biosystems Science and Engineering, ETH Zurich, ; Basel, Switzerland
                [10 ]ISNI 0000 0000 9071 0620, GRID grid.419538.2, Department of Genome Regulation, , Max Planck Institute for Molecular Genetics, ; Berlin, Germany
                [11 ]ISNI 000000041936754X, GRID grid.38142.3c, Department of Stem Cell and Regenerative Biology, , Harvard University, ; Cambridge, MA USA
                [12 ]ISNI 0000 0000 9116 4836, GRID grid.14095.39, Institute of Chemistry and Biochemistry, , Freie Universität Berlin, ; Berlin, Germany
                [13 ]ISNI 0000000419368956, GRID grid.168010.e, Center for Personal Dynamic Regulomes, Howard Hughes Medical Institute, , Stanford University, ; Stanford, CA USA
                [14 ]ISNI 0000 0001 1811 6966, GRID grid.7722.0, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, ; Barcelona, Spain
                [15 ]ISNI 0000 0001 2172 2676, GRID grid.5612.0, Research Program on Biomedical Informatics, , Universitat Pompeu Fabra, ; Barcelona, Spain
                [16 ]ISNI 0000 0000 9601 989X, GRID grid.425902.8, Institució Catalana de Recerca i Estudis Avançats, ; Barcelona, Spain
                [17 ]ISNI 0000 0004 0604 7563, GRID grid.13992.30, Department of Computer Science and Applied Mathematics, Weizmann Institute of Science, ; Rehovot, Israel
                [18 ]ISNI 0000 0004 1784 4496, GRID grid.410720.0, Center for Genome Engineering, Institute for Basic Science, ; Daejon, Republic of Korea
                Author information
                http://orcid.org/0000-0002-1339-5959
                http://orcid.org/0000-0003-1420-9051
                http://orcid.org/0000-0002-4264-2285
                http://orcid.org/0000-0002-9544-8339
                http://orcid.org/0000-0002-3299-5597
                http://orcid.org/0000-0001-8646-7469
                http://orcid.org/0000-0002-9459-4393
                http://orcid.org/0000-0003-4925-8988
                http://orcid.org/0000-0002-6859-1164
                http://orcid.org/0000-0003-4847-1306
                Article
                272
                10.1038/s41576-020-0272-6
                7444682
                32839576
                f52232eb-cd82-44be-aa92-c1221f4bec8a
                © Springer Nature Limited 2020

                This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.

                History
                : 21 July 2020
                Categories
                Viewpoint

                genetics,genomics,genetic techniques
                genetics, genomics, genetic techniques

                Comments

                Comment on this article